Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Pooled cohort 1 results from the phase 2 REFINE trial demonstrated durable responses and potential disease modification from the addition of navitoclax to ongoing ruxolitinib in relapsed/refractory myelofibrosis.